bioxcel - Search News

BioXcel, common stock

BioXcel Therapeutics Announces Reverse Stock Split

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it will effect a 1-for-16 reverse stock split of its common stock.

Business Insider · 22h

BioXcel Therapeutics Sets 1-for-16 Reverse Stock Split To Regain Nasdaq Listing

(RTTNews) - BioXcel Therapeutics, Inc. (BTAI), Thursday announced a reverse stock split of 1-for-16 to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The company's shares are expected to trade on a split adjusted basis beginning February 10, 2025.

ETF Daily News · 4d

BioXcel Therapeutics Holds Special Meeting, Approves Reverse Stock Split Plan

BioXcel Therapeutics, Inc. conducted a special meeting of stockholders to decide on crucial matters. The meeting saw the participation of 30,360,492 shares of common stock, either in person or represented by proxy,

1don MSN

BioXcel Therapeutics advances key clinical trials

NEW HAVEN, Conn. - BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company focused on artificial ...

BioXcel Therapeutics Provides Clinical and Business Update

Patient enrollment advancing in SERENITY At-Home Phase 3 trial of BXCL501 for acute treatment of agitation associated with ...

Nasdaq1mon

BioXcel Therapeutics downgraded to Underperform from Buy at BofA

BofA analyst Alec Stranahan downgraded BioXcel Therapeutics (BTAI) to Underperform from Buy with a price target of 25c, down from $7. The firm cites an “uncertain” agitation market opportunity ...

What is HC Wainwright’s Forecast for BTAI FY2024 Earnings?

Equities research analysts at HC Wainwright raised their FY2024 EPS estimates for shares of BioXcel Therapeutics in a ...

22hon MSN

BioXcel Therapeutics announces 1-for-16 reverse stock split

NEW HAVEN, Conn. - BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company focused on developing medicines in neuroscience through artificial intelligence, has declared a 1-for-16 ...

BioXcel Therapeutics provides clinical, business update

BioXcel Therapeutics (BTAI) provided an update on the progress of its late-stage clinical programs for lead neuroscience asset BXCL501, as well ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results